United Therapeutics (NASDAQ:UTHR) CEO Sells $5,201,155.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, June 8th. The shares were sold at an average price of $547.49, for a total value of $5,201,155.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,180,462.37. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $545.40 on Friday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market cap of $23.15 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The business’s fifty day moving average is $567.24 and its 200-day moving average is $521.17.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts predict that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Avoro Capital Advisors LLC boosted its position in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP boosted its position in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares during the period. Janus Henderson Group PLC boosted its position in shares of United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the third quarter worth $317,617,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.